Skip to ContentSkip to Navigation
About us Practical matters How to find us dr. D.G. Knapen


Immune checkpoint inhibitor-mediated polymyalgia rheumatica versus primary polymyalgia rheumatica: comparison of disease characteristics and treatment requirement

Search for novel cancer treatments and reducing their side effects

Abstract 5611: LAG-3 PET imaging in patients with cancer before immune checkpoint inhibitor therapy

Opportunities on the horizon for the management of early colon cancer

Potential, Limitations and Risks of Cannabis-Derived Products in Cancer Treatment

89Zr-3,2-HOPO-mesothelin antibody PET imaging reflects tumor uptake of mesothelin targeted 227Th-conjugate therapy in mice

Abstract CT207: A phase 1 open-label, dose escalation and expansion trial to investigate the safety, pharmacokinetics and pharmacodynamics of CB307, a Trispecific Humabody® T-cell enhancer, in patients with PSMA+ advanced and/or metastatic solid tumors (POTENTIA)

Molecular imaging to support cancer immunotherapy

Lessons learnt from scoring adjuvant colon cancer trials and meta-analyses using the ESMO-Magnitude of Clinical Benefit Scale V.1.1

Reconsider radiation exposure from imaging during immune checkpoint inhibitor trials to reduce risk of secondary cancers in long-term survivors?

Read more


Podcast over het coloncarcinoom